Neutralizing human IgG4 monoclonal antibody against human TNF-α

Anti-hTNF-α-hIgG4 is a neutralizing monoclonal antibody featuring the constant region of the human IgG4 isotype and the variable region of adalimumab. Adalimumab is a fully human monoclonal antibody against the pro-inflammatory cytokine human tumor necrosis factor alpha (hTNF-α). Adalimumab binds to TNF-α and blocks its interaction with TNF receptors thereby downregulating the inflammatory reactions associated with autoimmune diseases, such as rheumatoid arthritis and Crohn’s disease. Anti-hTNF-α-hIgG4 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G. The neutralizing activity of this human IgG4 antibody was determined using HEK-Blue™ TNF-α/IL-1β cells.


ND50 (50% neutralizing dose):  ~ 2 - 5 ng/ml  for 4 ng/ml human TNF-α in HEK-Blue™ TNF-α/IL-1β cells
Monoclonal antibody
Application: Neutralization of human TNF-α-induced cellular activation
Specificity: Human TNF-α
Isotype: Human IgG4
Formulation: 0.2 µm filtered solution in 75 mM phosphate buffer with 100 mM glycine, 5% w/v saccharose and stabilizing agents


100 µg purified anti-hTNFα-hIgG4 antibody, provided azide-free and lyophilized



Cat. Codehtnfa-mab4
Unit Size100 µg
Price For price or distributor address,
please select your country
Disclaimer: Our products are provided for research purpose only. Commercial applications may require licensing from third parties.
Note that the sequence of available ORFs provided by InvivoGen can differ from a given reference Genbank record due to genetic variations and/or alternative splicing. Customers should verify that the version of a gene sold by InvivoGen is suitable for the customer needs.
Copyrights © 2011-2016 InvivoGen. All Rights Reserved. Reproduction of any materials from this site is strictly forbidden without permission for commercial use. Nonprofit use for non-commercial research and educational purposes is permitted, citation should include the URL "".